Drug Profile
Research programme: CCR5 antagonists - Novita Healthcare/TargetDrug
Alternative Names: CCR5 inhibitors - Novita Healthcare/TargetDrugLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator TargetDrug
- Developer Novita Healthcare; TargetDrug
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in Australia (Topical, Gel)
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in China (Topical, Gel)
- 05 Aug 2009 Monogram Biosciences has been acquired by Laboratory Corporation of America Holdings